Table 1.
NAFLD activity scores
| Age |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12 weeks |
52 weeks |
||||||||
| Genotype | Scale | Wild-type | F-IGFRKO | F-IRKO | F-IR/IGFRKO | Wild-type | F-IGFRKO | F-IRKO | F-IR/IGFRKO |
| Macrovesicular steatosis | 0–3 | 0 | 0 | 1.7 ± 0.4 | 2.6 ± 0.2 | 0.2 ± 0.2 | 0 | 2.8 ± 0.2 | 2.3 ± 0.2 |
| Portal inflammation | 0–3 | 0 | 0 | 0.4 ± 0.2 | 0 | 0 | 1.0 ± 0.0 | 0.6 ± 0.2 | 1.5 ± 0.2 |
| Ballooning degeneration | 0–2 | 0 | 0 | 1.9 ± 0.1 | 1.6 ± 0.2 | 0 | 0.2 ± 0.2 | 2.0 ± 0.0 | 1.3 ± 0.2 |
| Interstitial fibrosis, stage | 0–4 | 0 | 0 | 0.1 ± 0.1 | 0 | 0 | 0 | 0.8 ± 0.4 | 2.7 ± 0.2 |
| Fibrosis present, % total | 0 | 0 | 14 | 0 | 0 | 0 | 60 | 100 | |
Results are mean ± SEM of 4 to 6 mice per group. NAFLD activity scores were assessed in H&E- and trichrome-stained liver sections of 12- and 52-week-old mice by a practicing clinical pathologist who adopted a modified version of a previously published method (40).